HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH RSS TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Figures Only Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Related articles in JNM Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Rutar, F. J. Articles by Vose, J. M. Search for Related Content PubMed PubMed Citation Articles by Rutar, F. J. Articles by Vose, J. M.

Outpatient Treatment with ¹³¹I-Anti-B1 Antibody: Radiation Exposure to Family Members

Departments of Chemical and Radiation Safety, Pharmacy Practice, Pathology and Microbiology, Internal Medicine, and Radiology, University of Nebraska Medical Center, Omaha, Nebraska; Department of Hematology/Oncology, University of California, San Francisco, and Corixa Corp., South San Francisco, California; and Nuclear Physics Enterprises, Cherry Hill, New Jersey

The Nuclear Regulatory Commission (NRC) regulations that govern release of patients administered radioactive material have been revised to include dose-based criteria in addition to the conventional activity-based criteria. A licensee may now release a patient if the total effective dose equivalent to another individual from exposure to the released patient is not likely to exceed 5 mSv (500 mrem). The result of this dose-based release limit is that now many patients given therapeutic amounts of radioactive material no longer require hospitalization. This article presents measured dose data for 26 family members exposed to 22 patients treated for non-Hodgkin’s lymphoma with ¹³¹I-anti-B1 antibody after their release according to the new NRC dose-based regulations. Methods: The patients received administered activities ranging from 0.94 to 4.77 GBq (25–129 mCi). Family members were provided with radiation monitoring devices (film badges, thermoluminescent or optically stimulated luminescent dosimeters, or electronic digital dosimeters). Radiation safety personnel instructed the family members on the proper wearing and use of the devices. Instruction was also provided on actions recommended to maintain doses to potentially exposed individuals as low as is reasonably achievable. Results: Family members wore the dosimeters for 2–17 d, with the range of measured dose values extending from 0.17 to 4.09 mSv (17–409 mrem). The average dose for infinite time based on dosimeter readings was 32% of the predicted doses projected to be received by the family members using the NRC method provided in regulatory guide 8.39. Conclusion: Therapy with ¹³¹I-anti-B1 antibody can be conducted on an outpatient basis using the established recommended protocol. The patients can be released immediately with confidence that doses to other individuals will be below the 5-mSv (500 mrem) limit.

Key Words: release criteria • radionuclide therapy • radiation safety • monoclonal antibody therapy

Related articles in JNM:

Investigation of Patient Release Criteria

Michael G. Stabin
JNM 2001 42: 916. [Full Text]  

This article has been cited by other articles:

				P. Z. Pace-Asciak, R. J. Payne, S. J. Eski, P. Walfish, M. Damani, and J. L. Freeman Cost Savings of Patients With a MACIS Score Lower Than 6 When Radioactive Iodine Is Not Given Arch Otolaryngol Head Neck Surg, September 1, 2007; 133(9): 870 - 873. [Abstract] [Full Text] [PDF]

				J. G. Hunt, D. Nosske, and D. S. dos Santos Estimation of the dose to the nursing infant due to direct irradiation from activity present in maternal organs and tissues Radiat Prot Dosimetry, April 28, 2005; 113(3): 290 - 299. [Abstract] [Full Text] [PDF]

				J. M. Vose Bexxar(R): Novel Radioimmunotherapy for the Treatment of Low-Grade and Transformed Low-Grade Non-Hodgkin's Lymphoma Oncologist, April 1, 2004; 9(2): 160 - 172. [Abstract] [Full Text] [PDF]

				D. W. Seldin Techniques for Using Bexxar for the Treatment of Non-Hodgkin's Lymphoma* J. Nucl. Med. Technol., September 1, 2002; 30(3): 109 - 114. [Abstract] [Full Text] [PDF]

				R. O. Dillman Radiolabeled Anti-CD20 Monoclonal Antibodies for the Treatment of B-Cell Lymphoma J. Clin. Oncol., August 15, 2002; 20(16): 3545 - 3557. [Full Text] [PDF]

				J. A. Siegel, S. Kroll, D. Regan, M. S. Kaminski, and R. L. Wahl A Practical Methodology for Patient Release After Tositumomab and 131I-Tositumomab Therapy J. Nucl. Med., March 1, 2002; 43(3): 354 - 363. [Abstract] [Full Text] [PDF]

				C. D. Venencia, A. G. Germanier, S. R. Bustos, A. A. Giovannini, and E. P. Wyse Hospital Discharge of Patients with Thyroid Carcinoma Treated with 131I J. Nucl. Med., January 1, 2002; 43(1): 61 - 65. [Abstract] [Full Text] [PDF]

				M. G. Stabin Investigation of Patient Release Criteria J. Nucl. Med., June 1, 2001; 42(6): 916 - 916. [Full Text] [PDF]